Mariam-Eleni Oraiopoulou

Dr. Mariam-Eleni Oraiopoulou

Cancer Research UK, University of Cambridge

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MOMariam-Eleni Oraiopoulou
Mariam-Eleni Oraiopoulou
ETEleftheria Tzamali
Eleftheria Tzamali
GTGeorgios Tzedakis
Georgios Tzedakis
AVA. Vakis
A. Vakis
JPJ. Papamatheakis
J. Papamatheakis
Vangelis SakkalisVangelis Sakkalis
Vangelis Sakkalis
The application of accurate cancer predictive algorithms validated with experimental data is a field concerning both basic researchers and clinicians, especially regarding a highly aggressive form of cancer, such as Glioblastoma. In an aim to enhance prediction accuracy in realistic patient-specific environments, accounting for both inter- and intratumoral heterogeneity, we use patient-derived Glioblastoma cells from different patients. We focus on cell proliferation using in vitro experiments to estimate cell doubling times and sizes for established primary Glioblastoma cell lines. A preclinically driven mathematical model parametrization is accomplished by taking into account the experimental measurements. As a control cell line we use the well-studied U87MG cells. Both in vitro and in silico results presented support that the variance between tumor staging can be attributed to the differential proliferative capacity of the different Glioblastoma cells. More specifically, the intratumoral heterogeneity together with the overall proliferation reflected in both the proliferation rate and the mechanical cell contact inhibition can predict the in vitro evolution of different Glioblastoma cell lines growing under the same conditions. Undoubtedly, additional imaging techniques capable of providing spatial information of tumor cell physiology and microenvironment will enhance our understanding regarding Glioblastoma nature and verify and further improve our predictability.

1 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MOMariam-Eleni Oraiopoulou
Mariam-Eleni Oraiopoulou
ETEleftheria Tzamali
Eleftheria Tzamali
GTGeorgios Tzedakis
Georgios Tzedakis
ELE. Liapis
E. Liapis
GZG. Zacharakis
G. Zacharakis
Vangelis SakkalisVangelis Sakkalis
Vangelis Sakkalis
Glioblastoma cells adopt migration strategies to invade into the brain parenchyma ranging from individual to collective mechanisms, whose role and dynamics are not yet fully understood. In this work, we explore Glioblastoma heterogeneity and recapitulate its invasive patterns both in vitro, by utilizing primary cells along with the U87MG cell line, and in silico, by adopting discrete, individual cell-based mathematics. Glioblastoma cells are cultured three-dimensionally in an ECM-like substrate. The primary Glioblastoma spheroids adopt a novel cohesive pattern, mimicking perivascular invasion in the brain, while the U87MG adopt a typical, starburst invasive pattern under the same experimental setup. Mathematically, we focus on the role of the intrinsic heterogeneity with respect to cell-to-cell adhesion. Our proposed mathematical approach mimics the invasive morphologies observed in vitro and predicts the dynamics of tumour expansion. The role of the proliferation and migration is also explored showing that their effect on tumour morphology is different per cell type. The proposed model suggests that allowing cell-to-cell adhesive heterogeneity within the tumour population is sufficient for variable invasive morphologies to emerge which remain originally undetectable by conventional imaging, indicating that exploration in pathological samples is needed to improve our understanding and reveal potential patient-specific therapeutic targets.

1 August 2019 in Tissue and Cell
Verified
Journal Article
Closed access
MOMariam-Eleni Oraiopoulou
Mariam-Eleni Oraiopoulou
MTMaria Tampakaki
Maria Tampakaki
ETEleftheria Tzamali
Eleftheria Tzamali
TTTheodoros Tamiolakis
Theodoros Tamiolakis
VMVenediktos Makatounakis
Venediktos Makatounakis
JPJoseph (Sifis) Papamatheakis
Joseph (Sifis) Papamatheakis

10 September 2021 in IEEE Reviews in Biomedical Engineering
Verified
Journal Article
Closed access
MOMariam-Eleni Oraiopoulou
Mariam-Eleni Oraiopoulou
ETEleftheria Tzamali
Eleftheria Tzamali
JPJoseph (Sifis) Papamatheakis
Joseph (Sifis) Papamatheakis
Vangelis SakkalisVangelis Sakkalis
Vangelis Sakkalis
The main reason why therapeutic schemes fail in Glioblastoma lies on its own peculiarities as a cancer and on our failure to fully decipher them. Fast tumor evolution, invasiveness and incomplete surgical resection contribute to disease recurrence, therapy resistance and high mortality. More faithfull models must be developed to address Glioblastoma biology and better clinical guidance. Research studies are discussed in this review that: i) improve understanding and assessment of the growth mechanisms of Glioblastoma and ii) develop preclinical models (in vitro-in vivo-in silico) that mimic patients tumor (phenocopying) in order to provide better prediction of response to therapies.

Verified
Journal Article
Open access
PDF file
MTMaria Tampakaki
Maria Tampakaki
MOMariam-Eleni Oraiopoulou
Mariam-Eleni Oraiopoulou
ETEleftheria Tzamali
Eleftheria Tzamali
GTGeorgios Tzedakis
Georgios Tzedakis
TMTakis Makatounakis
Takis Makatounakis
Vangelis SakkalisVangelis Sakkalis
Vangelis Sakkalis
Glioblastoma is the most malignant brain tumor among adults. Despite multimodality treatment, it remains incurable, mainly because of its extensive heterogeneity and infiltration in the brain parenchyma. Recent evidence indicates dysregulation of the expression of the Promyelocytic Leukemia Protein (PML) in primary Glioblastoma samples. PML is implicated in various ways in cancer biology. In the brain, PML participates in the physiological migration of the neural progenitor cells, which have been hypothesized to serve as the cell of origin of Glioblastoma. The role of PML in Glioblastoma progression has recently gained attention due to its controversial effects in overall Glioblastoma evolution. In this work, we studied the role of PML in Glioblastoma pathophysiology using the U87MG cell line. We genetically modified the cells to conditionally overexpress the PML isoform IV and we focused on its dual role in tumor growth and invasive capacity. Furthermore, we targeted a PML action mediator, the Enhancer of Zeste Homolog 2 (EZH2), via the inhibitory drug DZNeP. We present a combined in vitro–in silico approach, that utilizes both 2D and 3D cultures and cancer-predictive computational algorithms, in order to differentiate and interpret the observed biological results. Our overall findings indicate that PML regulates growth and invasion through distinct cellular mechanisms. In particular, PML overexpression suppresses cell proliferation, while it maintains the invasive capacity of the U87MG Glioblastoma cells and, upon inhibition of the PML-EZH2 pathway, the invasion is drastically eliminated. Our in silico simulations suggest that the underlying mechanism of PML-driven Glioblastoma physiology regulates invasion by differential modulation of the cell-to-cell adhesive and diffusive capacity of the cells. Elucidating further the role of PML in Glioblastoma biology could set PML as a potential molecular biomarker of the tumor progression and its mediated pathway as a therapeutic target, aiming at inhibiting cell growth and potentially clonal evolution regarding their proliferative and/or invasive phenotype within the heterogeneous tumor mass.

22 October 2024 in Advanced Science
Verified
Journal Article
Open access
ABAdrian Buehler
Adrian Buehler
EBEmma L. Brown
Emma L. Brown
ENEmmanuel Nedoschill
Emmanuel Nedoschill
Markus EcksteinMarkus Eckstein
Markus Eckstein
PLPetra Ludwig
Petra Ludwig
ARAdrian Regensburger
Adrian Regensburger
The analysis of vascular morphology and functionality enables the assessment of disease activity and therapeutic effects in various pathologies. Raster‐scanning optoacoustic mesoscopy (RSOM) is an imaging modality that enables the visualization of superficial vascular networks in vivo. In murine models of colitis, deep vascular networks in the colon wall can be visualized by transrectal absorber guide raster‐scanning optoacoustic mesoscopy (TAG‐RSOM). In order to accelerate the implementation of this technology in translational studies of inflammatory bowel disease, an image‐processing pipeline for TAG‐RSOM data has been developed. Using optoacoustic data from a murine model of chemically‐induced colitis, different image segmentation methods are compared for visualization and quantification of deep vascular patterns in terms of vascular network length and complexity, blood volume, and vessel diameter. The presented image‐processing pipeline for TAG‐RSOM enables label‐free in vivo assessment of changes in the vascular network in murine colitis with broad applications for inflammatory bowel disease research.